Journey Medical Corp (DERM) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Journey Medical Corp is a commercial-stage pharmaceutical company focused on dermatological conditions. It operates as a controlled subsidiary of Fortress Biotech, Inc. The company markets nine FDA-approved prescription drugs, with Emrosi (minocycline) being a key growth driver following its launch in early 2025.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Total Revenue | $18.51 million | $34.47 million | $28.15 million |
| Net Loss | $(0.31) million | $(2.54) million | $(7.87) million |
| Operating Income (Loss) | $0.46 million | $(1.04) million | $(6.20) million |
| Cash and Equivalents | $25.64 million (as of June 30, 2026) | ||
| Working Capital | $27.0 million (as of June 30, 2026) | ||
| Total Debt (Principal) | $25.0 million | ||
| Operating Cash Flow (YTD) | $1.18 million provided |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 22% year-to-date. This was primarily driven by Emrosi sales, which grew 189% in Q2 to $8.07 million.
- Profitability Improvement: The company achieved an operating profit of $0.46 million in Q2 2026, a significant turnaround from an operating loss of $2.88 million in Q2 2025. The net loss narrowed by 92% year-over-year.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 8% in Q2 and 6% YTD, largely due to reduced launch costs for Emrosi compared to the prior year.
- Product Mix: While Emrosi grew significantly, legacy products like Qbrexza and Accutane saw declines of 26% and 1% respectively in Q2, attributed to coverage mix changes and generic competition.
- New Revenue Stream: The company recognized $0.67 million in "Other Revenue" in Q2 2026 from supply agreements and royalties related to Amzeeq sales by Cutia Therapeutics in China, a new revenue stream not present in the prior year.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date due to recurring historical losses, despite recent operational improvements.
- Debt Structure: The company holds a $25 million term loan with SWK Funding. A Third Amendment in September 2025 extended the maturity to June 2028 and deferred principal repayments until February 2027, contingent on meeting a $60 million trailing twelve-month revenue threshold (which was met as of Dec 31, 2025).
- Capital Resources: The company maintains an At-The-Market (ATM) sales agreement allowing for the sale of up to 3.75 million shares and a $150 million shelf registration (2026 Shelf) for future equity or debt offerings.
- Risk Factors: Key risks include dependence on Emrosi commercialization, potential generic competition for existing products, regulatory changes, and the need for additional capital to fund operations and R&D.
- Legal Proceedings: The company is involved in a routine vendor dispute regarding service charges; the outcome is uncertain, and a material loss cannot be reasonably estimated at this time.
Investor Verification Checklist
- Going Concern Status: Verify the company's specific plans to address the "substantial doubt" disclosure and assess the runway of current cash ($25.6M) against burn rates.
- Emrosi Trajectory: Monitor quarterly Emrosi sales growth to ensure it sustains the revenue levels required to maintain the deferred principal payment status on the SWK loan.
- Debt Covenants: Review the specific revenue and liquidity covenants in the SWK Credit Facility to ensure continued compliance.
- Legacy Product Decline: Assess the rate of decline in Qbrexza and Accutane revenues to determine if Emrosi growth is fully offsetting legacy erosion.
- Vendor Dispute: Monitor updates on the vendor dispute to evaluate potential financial impact.